GO:0044594 17-beta-hydroxysteroid dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044594 defines the NAD+-dependent oxidation of a 17-beta-hydroxysteroid to a 17-oxosteroid, producing NADH and H+ [1,2].
• This activity is central to steroid hormone metabolism, influencing estrogen, androgen, and neurosteroid levels in peripheral tissues [1,3,6].
• Enzymes with this activity include members of the short-chain dehydrogenase/reductase (SDR) and aldo-keto reductase (AKR) superfamilies.
• Dysregulation of 17-beta-hydroxysteroid dehydrogenase (NAD+) activity is implicated in hormone-dependent cancers such as breast cancer and meningioma [1,3,7].
• The activity is regulated by steroid hormones, retinoic acid, and intracellular factors, affecting local hormone bioavailability [2,7,8].
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of this activity in disease and metabolism.
Description
17-beta-hydroxysteroid dehydrogenase (NAD+) activity (GO:0044594) is a molecular function that catalyzes the reversible conversion of a 17-beta-hydroxysteroid to a 17-oxosteroid using NAD+ as the electron acceptor [1,2]. This reaction is pivotal in steroid hormone metabolism, as it modulates the potency of androgens and estrogens in target tissues [1,3]. The activity is attributed to several enzymes, including type 2 17-beta-hydroxysteroid dehydrogenase (17beta-HSD2) and certain aldo-keto reductases, which exhibit distinct substrate specificities and tissue distributions [1,5]. Researchers study this activity to understand hormone-dependent physiology and pathologies, such as breast cancer, meningioma, and reproductive disorders [1,3,7]. The NAD+ dependence distinguishes it from NADP+-preferring isoforms, making it a unique target for selective modulation.
17-beta-hydroxysteroid dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0044594 |
|---|---|
| GO term | 17-beta-hydroxysteroid dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Catalyzes the NAD+-dependent oxidation of 17-beta-hydroxysteroids to 17-oxosteroids |
| Reaction | 17-beta-hydroxysteroid + NAD+ = 17-oxosteroid + NADH + H+ |
| Cofactor | NAD+ |
| Substrate class | 17-beta-hydroxysteroids (e.g., estradiol, testosterone) |
| Product class | 17-oxosteroids (e.g., estrone, androstenedione) |
What Is GO:0044594?
According to QuickGO, GO:0044594 describes the catalysis of the reaction: a 17-beta-hydroxysteroid + NAD+ = a 17-oxosteroid + NADH + H+. In other words, it is the NAD+-dependent oxidation of the hydroxyl group at carbon 17 of a steroid, converting it to a ketone, with concomitant reduction of NAD+ to NADH [1,2].
Why Is 17-beta-hydroxysteroid dehydrogenase (NAD+) activity Important in Cell Biology?
This activity is essential for regulating the local concentration of active steroid hormones, thereby influencing processes such as cell proliferation, differentiation, and apoptosis [1,3,7]. Its dysregulation can lead to altered hormone signaling, which is a hallmark of hormone-dependent cancers and metabolic disorders [1,6]. Understanding GO:0044594 provides insights into the mechanisms of endocrine resistance and offers potential targets for therapeutic intervention.
• Controls the balance between active and inactive steroid hormones in peripheral tissues [1,3].
• Modulates estrogen and androgen action in breast, prostate, and endometrial tissues [6,7].
• Plays a role in neurosteroid metabolism and meningioma biology [1,3].
• Influences reproductive physiology, including uterine function.
• Is a target for inhibitors aimed at treating hormone-dependent cancers.
• Regulated by retinoic acid and steroid hormones, linking to nuclear receptor signaling [7,8].
• Distinct from NADP+-dependent isoforms, allowing selective targeting.
• Contributes to intracellular redox balance via NADH production.
• Involved in the metabolism of androgens and estrogens, affecting cancer risk [1,6].
• Provides a model for studying SDR and AKR enzyme families.
What Happens During 17-beta-hydroxysteroid dehydrogenase (NAD+) activity?
Substrate Binding and Orientation
In simple terms: The enzyme grabs the steroid hormone and positions it next to NAD+.
The enzyme binds a 17-beta-hydroxysteroid (e.g., estradiol or testosterone) in a pocket that orients the C17 hydroxyl group toward the catalytic residues and the nicotinamide ring of NAD+ [1,2]. This binding is stereospecific, ensuring oxidation at the 17-beta position.
Hydride Transfer and Oxidation
In simple terms: A hydride is removed from the steroid and transferred to NAD+, turning the alcohol into a ketone.
A catalytic base abstracts a proton from the hydroxyl group, while a hydride is transferred to NAD+, forming NADH and a 17-oxosteroid (e.g., estrone or androstenedione) [1,2]. This step is rate-limiting and depends on the redox state of the cell.
Product Release and Enzyme Turnover
In simple terms: The products leave, and the enzyme is ready for another round.
NADH and the 17-oxosteroid are released, allowing the enzyme to bind new substrate. The reaction is reversible, but the NAD+/NADH ratio typically favors oxidation in vivo [2,5].
Intracellular Regulation of Catalytic Activity
In simple terms: The cell can speed up or slow down this reaction by changing the enzyme or its environment.
In A431 cells, 17-beta-HSD type 2 activity is regulated by intracellular factors, possibly through post-translational modifications or interactions with other proteins. Retinoic acid treatment increases estradiol 17-beta-HSD activity in T47D breast cancer cells, indicating transcriptional regulation.
Key Genes Involved in GO:0044594 17-beta-hydroxysteroid dehydrogenase (NAD+) activity
The following genes and proteins are associated with 17-beta-hydroxysteroid dehydrogenase (NAD+) activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HSD17B2 | Encodes type 2 17-beta-hydroxysteroid dehydrogenase, a NAD+-dependent enzyme that inactivates estradiol and testosterone | Correlates with mRNA abundance in meningioma; regulated in A431 cells [1,2] |
| HSD17B1 | Encodes type 1 17-beta-HSD, primarily NADPH-dependent but can exhibit NAD+ activity under certain conditions | Studied in breast cancer and steroid metabolism |
| HSD17B3 | Encodes type 3 17-beta-HSD, involved in testosterone synthesis | Target for androgen-related disorders |
| HSD17B5 | Encodes type 5 17-beta-HSD (AKR1C3), an aldo-keto reductase with NAD+ activity | Implicated in prostate cancer and steroid hormone metabolism |
| AKR1C1 | Aldo-keto reductase with 3(17)beta-HSD activity | Characterized in hamster; potential role in hormone metabolism |
| AKR1C2 | Aldo-keto reductase with 3(17)beta-HSD activity | Studied for steroid hormone inactivation |
| AKR1C3 | Aldo-keto reductase with 17-beta-HSD activity | Linked to prostate cancer and androgen synthesis |
| HSD17B7 | Encodes type 7 17-beta-HSD, involved in estradiol production | Studied in breast cancer and steroidogenesis |
| HSD17B10 | Encodes type 10 17-beta-HSD, multifunctional enzyme | Role in neurosteroid metabolism and neurodegeneration |
| HSD17B12 | Encodes type 12 17-beta-HSD, involved in fatty acid and steroid metabolism | Potential link to metabolic disorders |
| HSD17B13 | Encodes type 13 17-beta-HSD, associated with liver disease | Target for nonalcoholic steatohepatitis |
| HSD17B14 | Encodes type 14 17-beta-HSD, with NAD+ preference | Studied in hormone-dependent cancers |
| HSD17B6 | Encodes type 6 17-beta-HSD, involved in androgen metabolism | Role in prostate cancer |
| HSD17B8 | Encodes type 8 17-beta-HSD, part of the SDR family | Potential role in steroidogenesis |
| HSD17B11 | Encodes type 11 17-beta-HSD, with broad substrate specificity | Studied in lipid metabolism |
| HSD17B4 | Encodes type 4 17-beta-HSD, involved in peroxisomal fatty acid oxidation | Link to D-bifunctional protein deficiency |
How Is 17-beta-hydroxysteroid dehydrogenase (NAD+) activity Regulated?
The activity of 17-beta-hydroxysteroid dehydrogenase (NAD+) is regulated at multiple levels. In A431 cells, intracellular factors modulate type 2 17-beta-HSD catalytic activity, possibly through post-translational mechanisms. Retinoic acid increases estradiol 17-beta-HSD expression and activity in T47D breast cancer cells, indicating transcriptional regulation via nuclear receptors. Steroidal control of rat uterine 17-beta-HSD activity suggests hormonal regulation in reproductive tissues. Additionally, the NAD+/NADH ratio influences the direction of the reaction, linking cellular redox state to enzyme activity.
17-beta-hydroxysteroid dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSD17B2 | Meningioma, breast cancer | Knockout in meningioma cell lines; overexpression in breast cancer cells [1,3] |
| HSD17B1 | Breast cancer, endometriosis | Point mutation to alter cofactor preference; knockout in MCF-7 cells |
| HSD17B10 | Alzheimer's disease, neurodegeneration | Knock-in of disease-associated mutations in neurons |
| AKR1C3 | Prostate cancer, androgen excess | Knockout in LNCaP cells; overexpression in prostate fibroblasts |
| HSD17B13 | Nonalcoholic steatohepatitis | Knockout in hepatocytes; knock-in of protective variant |
Hormone-Dependent Cancers
Altered 17-beta-hydroxysteroid dehydrogenase (NAD+) activity affects local estrogen and androgen levels, contributing to breast cancer and prostate cancer progression [1,6]. In meningioma, 17-beta-HSD activity correlates with type-2 17-beta-HSD mRNA abundance, suggesting a role in tumor growth [1,3]. Inhibitors of 17-beta-HSD are being explored as therapeutic agents.
Neurosteroid-Related Disorders
17-beta-HSD type 10 is involved in neurosteroid metabolism, and its dysfunction has been linked to Alzheimer's disease and other neurodegenerative conditions. The NAD+-dependent activity may influence neuronal excitability and cognitive function.
Reproductive and Metabolic Disorders
Dysregulation of 17-beta-HSD activity can lead to endometrial disorders, polycystic ovary syndrome, and metabolic syndrome [6,8]. Steroidal control of uterine 17-beta-HSD activity highlights its importance in reproductive physiology.
From 17-beta-hydroxysteroid dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HSD17B2 affect estrogen levels? | CRISPR knockout in breast cancer cell lines [1,6] |
| How does a point mutation in the catalytic site alter activity? | CRISPR point mutation (e.g., HSD17B2 Y191F) [2,6] |
| Can a disease-associated variant be corrected? | CRISPR knock-in of wild-type allele in patient-derived cells |
| Where is the enzyme localized in the cell? | Tagged knock-in with fluorescent protein |
| What is the effect of enzyme overexpression on hormone signaling? | CRISPR overexpression via safe-harbor locus |
| Which genes interact with HSD17B2? | CRISPR library screening with readout of steroid metabolism |
How to Study the 17-beta-hydroxysteroid dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric enzyme assay | Conversion of 17-beta-hydroxysteroid to 17-oxosteroid | Quantifying activity in cell lysates [1,2] |
| qRT-PCR | mRNA abundance of HSD17B genes | Correlating expression with activity [1,3] |
| Western blot | Protein expression and post-translational modifications | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization | Determining organelle targeting |
| CRISPR knockout | Loss-of-function effects | Identifying essential genes |
| CRISPR activation | Gain-of-function effects | Screening for regulators |
| Metabolomics | Steroid metabolite levels | Assessing pathway flux |
| NAD+/NADH ratio assay | Cellular redox state | Linking metabolism to activity |
Enzymatic Activity Assays
Radiometric or fluorometric assays using 14C-labeled steroids and NAD+ measure the conversion to 17-oxosteroids, as described for meningioma and A431 cells [1,2]. These assays are quantitative and can be adapted to high-throughput screening.
mRNA Abundance Analysis
Quantitative RT-PCR or RNA-seq can measure HSD17B2 mRNA levels, which correlate with enzyme activity in meningioma tumors [1,3]. This approach helps link transcriptional regulation to catalytic function.
Protein Detection and Localization
Western blotting and immunocytochemistry using specific antibodies can detect 17-beta-HSD protein and its subcellular localization. Tagged knock-in models enable live-cell imaging.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate 17-beta-hydroxysteroid dehydrogenase (NAD+) activity, using steroid-sensitive reporters or metabolite profiling.
How CRISPR Can Be Used to Study GO:0044594 17-beta-hydroxysteroid dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of HSD17B2 or AKR1C3 can abolish 17-beta-hydroxysteroid dehydrogenase (NAD+) activity, revealing its role in hormone-dependent cell proliferation [1,6]. Knockout models are valuable for validating inhibitor specificity.
Point Mutation
Introducing point mutations in catalytic residues (e.g., the conserved Tyr in SDR enzymes) can dissect the mechanism of hydride transfer and cofactor preference [2,6]. Such models help distinguish NAD+ from NADP+ dependence.
Knock-in
Knock-in of disease-associated variants or tagged versions allows study of enzyme localization, stability, and function in a physiological context. This is particularly useful for modeling mutations found in cancer.
Overexpression
CRISPR-mediated overexpression of HSD17B2 or AKR1C3 can mimic hormone-refractory states in cancer cells, enabling studies of drug resistance and metabolic reprogramming [6,7].
How EDITGENE Supports 17-beta-hydroxysteroid dehydrogenase (NAD+) activity Research
Researchers studying 17-beta-hydroxysteroid dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in steroid metabolism, hormone-dependent cancer, or neurosteroid disorders. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for 17-beta-hydroxysteroid dehydrogenase (NAD+) activity research.
Frequently Asked Questions About 17-beta-hydroxysteroid dehydrogenase (NAD+) activity
What is 17-beta-hydroxysteroid dehydrogenase (NAD+) activity?
It is a molecular function (GO:0044594) that catalyzes the NAD+-dependent oxidation of a 17-beta-hydroxysteroid to a 17-oxosteroid, producing NADH and H+ [1,2].
What genes are involved in 17-beta-hydroxysteroid dehydrogenase (NAD+) activity?
Key genes include HSD17B2, HSD17B1, HSD17B3, AKR1C3, and other members of the SDR and AKR families [1,5,6].
How is 17-beta-hydroxysteroid dehydrogenase (NAD+) activity regulated?
It is regulated by intracellular factors, retinoic acid, steroid hormones, and the cellular NAD+/NADH ratio [2,7,8].
What diseases are associated with 17-beta-hydroxysteroid dehydrogenase (NAD+) activity?
Dysregulation is linked to breast cancer, meningioma, prostate cancer, neurodegeneration, and reproductive disorders [1,3,6].
What is the difference between NAD+ and NADP+ dependent 17-beta-HSD?
NAD+-dependent enzymes (GO:0044594) use NAD+ as cofactor, while NADP+-dependent isoforms prefer NADPH, affecting their role in catabolic versus anabolic pathways.
How can I measure 17-beta-hydroxysteroid dehydrogenase (NAD+) activity?
Radiometric enzyme assays, qRT-PCR for mRNA, Western blot, and metabolomics are commonly used [1,2,6].
Can CRISPR be used to study 17-beta-hydroxysteroid dehydrogenase (NAD+) activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies.
What are the substrates of 17-beta-hydroxysteroid dehydrogenase (NAD+)?
Substrates include estradiol, testosterone, and other 17-beta-hydroxysteroids [1,2].
What are the products of this reaction?
The products are 17-oxosteroids such as estrone and androstenedione, along with NADH and H+ [1,2].
Which cell lines are good models for studying this activity?
Meningioma cells, A431, T47D breast cancer cells, and LNCaP prostate cancer cells have been used [1,2,7].
Conclusion
17-beta-hydroxysteroid dehydrogenase (NAD+) activity (GO:0044594) is a critical molecular function in steroid hormone metabolism, with far-reaching implications for cancer, neurosteroid biology, and reproductive health [1,3,6]. Understanding its regulation and catalytic mechanism provides a foundation for developing targeted therapies. EDITGENE offers a full suite of CRISPR services to create precise cell models for studying this activity, empowering researchers to translate basic findings into clinical applications.
References
- 1. Carsol JL et al.. 1996. 17 beta-Hydroxysteroid dehydrogenase activity correlates with the type-2 17 beta-hydroxysteroid dehydrogenase mRNA abundance in human meningioma tumors.. Neuroendocrinology 64(1):70-8 PMID: 8811669
- 2. Blomquist CH et al.. 1997. Intracellular regulation of 17 beta-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cells.. J Endocrinol 153(3):453-64 PMID: 9204000
- 3. Carsol JL et al.. 1994. Characterization of 17 beta-hydroxysteroid dehydrogenase activity and mRNA abundance in human meningioma tumors.. Neuroendocrinology 60(4):445-51 PMID: 7824086
- 5. Endo S et al.. 2015. Characterization of hamster NAD+-dependent 3(17)β-hydroxysteroid dehydrogenase belonging to the aldo-keto reductase 1C subfamily.. J Biochem 158(5):425-34 PMID: 26002966
- 6. Poirier D. 2003. Inhibitors of 17 beta-hydroxysteroid dehydrogenases.. Curr Med Chem 10(6):453-77 PMID: 12570693
- 7. Reed MJ et al.. 1994. Regulation of estradiol 17 beta-hydroxysteroid dehydrogenase expression and activity by retinoic acid in T47D breast cancer cells.. Endocrinology 135(1):4-9 PMID: 8013376
- 8. Wahawisan R et al.. 1980. Steroidal control of rat uterine 17 beta-hydroxysteroid dehydrogenase activity.. Steroids 36(1):115 PMID: 6932105
